Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH-1 efimosfermin alfa in biopsy-confirmed F2/F3 MASH
2025-523675-39-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoints: Fibrosis improvement without worsening of steatohepatitis at Week 52, Resolution of steatohepatitis without worsening of fibrosis at Week 52 and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2025-523675-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523675-39-00.